EHC - European Haemophilia Consortium/LinkedIn
Oct 1, 2025, 16:30
Emicizumab Approvals in Europe: European Haemophilia Consortium Shares Key Updates
European Haemophilia Consortium (EHC) posted on LinkedIn:
”Indications of non-factor treatments for haemophilia A are evolving.
In Europe, Emicizumab is approved for routine prophylaxis for moderate haemophilia A with severe bleeding, for severe haemophilia A and for haemophilia A with factor VIII inhibitors.
It is always a good idea to consult local regulatory authorities for the precise current approved use in your area.
Learn more in the EHCucate topic Emicizumab Basics, available on the EHC Academy.”
Stay updated with Hemostasis Today.
-
Sep 15, 2026, 11:05Sudhir Kumar: Maternal Anemia May Shape a Child’s Brain Development
-
Sep 15, 2026, 10:48Ashok Singhal: A Life-Changing Transplant Brings New Hope for Beta Thalassemia
-
Sep 15, 2026, 10:33Vera Ghali: Mitapivat Opens a New Chapter in Thalassemia Treatment
-
Sep 15, 2026, 10:13Behnood Bikdeli: Exploring the Role of Antiphospholipid Antibodies in Ischemic Stroke
-
Sep 15, 2026, 09:55Mark Mamlouk: When Postpartum Headache Signals More Than a CSF Leak
-
Sep 15, 2026, 09:46Nicholas Raccagni: Heparin for VTE Prevention After Traumatic Brain Injury
-
Sep 15, 2026, 09:34Mario D. Caldararo: Are Lines of Zahn Pathognomonic for Antemortem Thrombosis?
-
Sep 15, 2026, 09:24Vishakha K. Kumar: ISTH Is Hiring – Exhibition and Sponsorship Operations Manager
-
Sep 15, 2026, 09:15Mark Mamlouk: The Hidden CSF Leak in Postpartum Headache